+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Viral Vector Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2035

  • PDF Icon

    Report

  • 150 Pages
  • November 2026
  • Region: Global
  • Lucintel
  • ID: 5909782
The global viral vector manufacturing market is expected to reach an estimated $5.9 million by 2035 from $2.1 million in 2027 with a CAGR of 13.6% from 2027 to 2035. The major drivers for this market are the increasing demand for scalable manufacturing technologies, the growing investments in biotechnology companies, and the rising demand for government funding for life sciences.

The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institute markets.
  • Within the type category, adeno-associated virus is expected to witness higher growth over the forecast period due to the high safety profile and gene therapy demand.
  • Within the end use category, pharmaceutical & biopharmaceutical is expected to witness the highest growth over the forecast period due to the rising biologics and advanced therapy development.
  • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the expanding biopharmaceutical manufacturing and research infrastructure.

Emerging Trends in Viral Vector Manufacturing Market

A shift in the viral vector manufacturing market is expected between 2025 and 2027, with more repeatable commercial-scale production. Growth will continue with the approval of more cell and gene therapies. In the meantime, manufacturers will increase their capacity and invest in process control and analytics. Lucintel expects continued growth, but pricing pressure and capacity constraints will continue.
  • Standardization of Platforms: Modular workflows for AAV and lentiviral vector production, coupled with faster turnaround times for single-use bioreactors, will decrease the time it takes to develop and transfer processes over the next 3-5 years.
  • Automation and Analytics: A greater understanding of the process and FDA guidance will help manufacture closed systems for real-time monitoring of viral vector production. Automation and analytics will improve batch-to-batch consistency of viral vector production.
  • Decentralization of Capacity: Decentralization of viral vector production will continue in North America and Europe, but the long-term viability of new capacity will depend on how the capacity is utilized.
  • Quality By Design: Pharmaceutical developers are placing a greater emphasis on the attributes of the active pharmaceutical ingredient (APIs), such as empty-to-full capsid ratio and residual DNA. Increasing stringency in the release testing will result in higher upfront costs, protect commercial dependability, and ensure brand integrity of biologics.
  • Cost-efficient Sustainability: Continuous improvements to single use bioprocessing systems reduce process requirement and increase flexibility; however, these improvements, along with increasing prices of raw materials, will have greater impact when combatted with Payers (i.e. insurance companies) scrutinizing the prices of treatments.
The next phase of the market will reward pharmaceutical manufacturers that can sustainably and reliably produce commercial quantities of potent AAV and lentiviral therapies. Continuous improvements in medicinal science to extend therapeutic action and access, including increase disease modifying potential, will fuel steady state growth in demands for these highly potent therapies.

Recent Developments in the Viral Vector Manufacturing Market

Between 2025 and 2027, the viral vector manufacturing market is expected to grow due to the advancement of gene therapy pipelines toward commercial supply. At this time, sponsors will also be seeking manufacturing capacity in regional locations. According to Lucintel, 2023 saw an increase in investment for manufacturing capacities beyond pilot suites. Process control and regulatory readiness were the main factors considered when selecting a manufacturing supplier.
  • Capacity Expansion: In 2025, Thermo Fisher’s viral vector manufacturing network spanned more than 20 locations worldwide. Ongoing investment in commercial-scale suites is expected to increase competition for distributed supply and accelerated technology transfer.
  • Consolidation: Also in 2025, a leading contract manufacturer reported more than 100 viral vector programs. Integration of development and commercial services is expected to continue.
  • Automation: In 2025, automation in processing platforms reduced batch process times by up to 30%. Further adoption of automation in AAV manufacturing is expected to improve productivity and reproducibility.
  • Regional Manufacturing: In July 2025, developers from Europe and North America announced the construction of bioreactor facilities of more than 2000 L. The construction of larger local manufacturing plants will ease the current dependence on international logistics for the transport of biologics, as well as meet local needs for reimbursement and supply.
  • Analytics Investment: In September 2025, suppliers in the industry launched assays that shortened timelines for release testing by approximately 50%. Refinement and characterization of biologics will aid regulatory submissions and reduce the time biologics are under a hold and the working capital tied to inventory.
In the next five years, the reliability of commercial output will affect the viral vector manufacturing market more than the size of the pipeline. Additions to capacity will alleviate bottlenecks, but batch economics and utilization will remain critical. In the process to reduce cost and risk for sponsors, platform processes at CDMOs will gain more market share. In addition, analytics and automation will be accepted by regulators to further scale biomanufacturing.

Strategic Growth Opportunities in the Viral Vector Manufacturing Market

The viral vector manufacturing market is shifting from bespoke clinical supply to repeatable commercial capacity. Lucintel expects the majority of cell and gene therapy candidates that will reach late-stage development between 2024 and 2026, to require stronger assurances of comparability and supply. They will track this shift as investments move to regional facilities, automation and specialized services.
  • Commercial-scale CDMO Capacity: In January 2025, more than 2,000 gene therapy studies were conducted globally. As candidates progress and sponsors advance multiple indications, the demand for a flexible multi-product manufacturing capacity will increase.
  • Non-viral and Hybrid Platforms: In March 2025, several sponsors progressed lipid nanoparticle (LNP) and other non-viral and hybrid technologies along with their viral vector programs. These hybrid technologies will gain interest over the next five years if they enable lower immunogenicity, larger payloads, and ease of revaccination.
  • Regional Manufacturing: In April 2025, the European Union had more than 35 of Advanced Therapy Medicinal Products approved. There will be greater on-shoring of vector production in alignment with government policies to reduce import dependencies and improve supply chain security and resiliency.
  • Automated Quality Control: In May 2025, we saw more than 1,000 active cell and gene therapy programs in regulatory filings. Technologies that allow for closed processing with lower deviation risk and better process comparability across sites will continue to gain traction and warrant a higher price.
  • Sustainable Process Inputs: In February 2025, single-use systems represented over 80% of bioprocessing system installations. Suppliers of single-use systems that enhance process and manufacturing sustainability with lower process waste, improved energy efficiency, and ease of purification will command more interest. Customers will prioritize total manufacturing emissions in their procurement decisions.
Over the next 5 years, the ability to integrate control of process and commercial considerations will differentiate winners. Continuous process improvement and secure capacity will be preferred. Regional production will gain traction to lower logistics risk while improving process and manufacturing sustainability and confidence with lower cost and improved digital process and quality assurance. Pressure will remain on margins for commoditized work; however, differentiated and protected vectors and aftermarket services will support margins.

Viral Vector Manufacturing Market Drivers and Challenges

The viral vector manufacturing market is influenced by a number of factors including rapid technology changes, increasing demand for advanced therapies, and investments made in the market. Similarly, the requirements and expectations of regulatory agencies continue to raise the bar for comparability and quality. Concurrently, developers of these therapies seek faster and lower cost methods of manufacturing to meet market demands. In this context, Lucintel expects strategic expansion of manufacturing capacities and continuous innovations to be the key drivers of the market over the next 3-5 years. Beyond this time frame, we anticipate that the market will experience the impacts of the high and rapid growth demands of increasingly complicated therapeutic products, while simultaneously needing to balance the requirements of reliable, steady-state production and compliance.

The factors responsible for driving this market include:

  • Increased Adoption of Cell and Gene Therapies: The expansion of the market for cell and gene therapies continues to fuel the growth of adeno-associated viral, lentiviral, and other vectors. It is expected that between 40-50 cell and gene therapies will be launched by 2025 in the major markets. New product candidates will continue to fuel the market for manufacturing, and product-specific requirements will increase the need for flexible facilities and specialized personnel.
  • Advances in Technology: Improved automation and closed processes along the bioprocessing chain led to a decrease in contamination and an increase in process efficiencies. Single-use technologies dominated the bioprocessing market and are expected to continue to do so. Advances in technologies to improve batch processes will enable manufacturers to produce smaller batch sizes and address the market needs for personalized therapies for rare diseases more efficiently.
  • Regulatory Support: Better regulatory direction for vector characterization and potency, and for sterility and comparability assessments, is helping agencies clarify what they expect, and are therefore helping to guide investment in qualified manufacturing capacity. During 2025, regulators in the United States and Europe released guidance and review decisions for advanced therapy products, and as such validated analytical methods became increasingly important. Regulatory standardization in the next three to five years will help reduce uncertainty, facilitate technology transfer, and build assurance in outsourcing manufacturing partners.
  • Capacity Expansion and Infrastructure Investment: Continued demand for commercial-scale vector production has prompted Pharma, and Contract Development and Manufacturing Organizations (CDMOs) to build new specialized facilities. In 2025, multiple industry plans for advanced therapy manufacturing capacities ran in the hundreds of millions of dollars. Improving the supply of facilities and locations for commercial manufacturing will alleviate pressure on the current manufacturing facilities and benefit larger clinical trials.
  • Product Innovation and Cost Optimization: To further improve a vector’s efficacy and reduce cost per dose, iterative design changes of vectors, cell lines and plasmids are being made. In 2025, many industry process development initiatives focused on incremental improvements in vector productivity. Continued product and process innovation will make advanced therapy products more accessible by improving their commercial viability.

The challenges facing this market include:

  • High Manufacturing Costs: In 2025, it is anticipated that manufacturing and quality-control costs will make up more than 20% of the development costs for advanced therapies. Challenges will continue to influence the market due to the need for process intensification, outsourcing, standardized platforms, and improved efficiency of analytical workflows to enable affordable dosing for greater access by patients.
  • Complex Processes and Scalability: The scale up from small-scale lab production to large-scale commercial production can affect vector quality, potency, and purity. In 2025, several developers were still reporting process development timelines in excess of 12 months before they were ready for large-scale commercial manufacturing. This challenge is expected to impact the market over the next 3 to 5 years and will affect the advancement of clinical programs due to process scalability and consistency. This can result in batch failures and limit the ability of manufacturers to serve both small-scale personalized therapies and larger, more commercialized indications.
  • Uncertainty in The Supply Chain and Regulations: Dependence on specialized plasmids, cell banks, resins, single-use components, and testing services creates supply-chain risks. In 2025, the lead times for critical manufacturing materials included several months, particularly for customized materials. Dual sourcing and production in the region will be encouraged. The market will also promote the use of larger supply buffers and the implementation of more stringent supplier qualification processes. Regulatory differences between countries will continue to complicate technology transfers and limit the commercialization of certain processes.
The viral vector manufacturing market is advancing due to improvements in production and regulatory frameworks and investments in relevant infrastructure and cost reduction. While time and expenses continue to limit the market, the next three to five years will be focused on automation and flexibility of facilities and processes. Resiliency of sourcing will be combined with advanced analytical methods. In the long-term, the market will depend on consistent improvements in technical production to provide reliable, affordable products.

List of Viral Vector Manufacturing Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies viral vector manufacturing market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.

Some of the viral vector manufacturing market companies profiled in this report include:

  • Merck
  • Lonza
  • Fujifilm Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent
  • Wuxi Biologics
  • Takara Bio
  • Waisman Biomanufacturing
  • Genezen Laboratories

Viral Vector Manufacturing Market by Segment

The study includes a forecast for the global viral vector manufacturing market by type, workflow, application, end use, and region.

Type [Value ($M) from 2019 to 2035]:

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus
  • Lentivirus
  • Plasmid DNA
  • Others

Workflow [Value ($M) from 2019 to 2035]:

  • Upstream Manufacturing
  • Downstream Manufacturing

Application [Value ($M) from 2019 to 2035]:

  • Cell & Gene Therapy
  • Vaccinology
  • Research & Other Applications

End Use [Value ($M) from 2019 to 2035]:

  • Pharmaceutical & Biopharmaceutical
  • Research Institutes
  • Others

Region [Value ($M) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Viral Vector Manufacturing Market

As expectations for quality, comparability and supply resilience increase, the viral vector manufacturing market is entering a capacity-building phase. Between 2025 and 2027, investments will be focused on process automation, modular facilities and regional production. Lucintel’s research revealed that these focus areas will be shaping supplier strategies in the upcoming years.
  • United States: Within the U.S., focus is on developing domestic capacity and standardizing regulatory frameworks. Thermo Fisher accelerated its investments in the U.S. manufacturing and research of biopharmaceuticals with an expected $2 billion spend over 4 years starting in 2025. This investment focused on reinforcing its supply of viral vectors and support the commercial launch of cell and gene therapies.
  • China: China is utilizing industrial policies to fund the expansion of local manufacturing. In March 2025, WuXi AppTec announced continued investments to advance its cell and gene therapy platforms and its viral-vector manufacturing facilities. These investments provide domestic supply of cell and gene therapy manufacturing and give Chinese sponsors the means to advance their programs without relying on overseas contract manufacturers.
  • Germany: Similar to China, Germany is also utilizing industrial policies to support manufacturing infrastructure and frameworks. In June 2025, Boehringer Ingelheim invested in its cell and gene therapy business to further build its viral-vector manufacturing capabilities to reinforce its European commercial supply.
  • India: The public and private sectors in India are making efforts to improve local biologics. The Department of Biotechnology continues to implement the BioE3 policy in January 2025. This policy promotes the development of biopharmaceutical manufacturing facilities and addresses advanced therapy products.
  • Japan: The public and private sectors in Japan are also making efforts to strengthen the local manufacturing of biologics. In April 2025, Takara Bio continued its investment to develop its GMP-grade cell and gene therapy manufacturing facility to provide viral vector services in Japan.

Features of the Global Viral Vector Manufacturing Market

  • Market Size Estimates: viral vector manufacturing market size estimation in terms of value ($M).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: viral vector manufacturing market size by various segments, such as by type, workflow, application, end use, and region in terms of value ($M).
  • Regional Analysis: viral vector manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, workflow, application, end use, and regions for the viral vector manufacturing market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vector manufacturing market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the viral vector manufacturing market by type (adenovirus, retrovirus, adeno-associated virus, lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and downstream manufacturing), application (cell & gene therapy, vaccinology, and research & other applications), end use (pharmaceutical & biopharmaceutical, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
3.6 Global Viral Vector Manufacturing Market Trends and Forecast
4. Global Viral Vector Manufacturing Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Adenovirus : Trends and Forecast (2019 to 2035)
4.4 Retrovirus : Trends and Forecast (2019 to 2035)
4.5 Adeno-Associated Virus : Trends and Forecast (2019 to 2035)
4.6 Lentivirus : Trends and Forecast (2019 to 2035)
4.7 Plasmid DNA : Trends and Forecast (2019 to 2035)
4.8 Others : Trends and Forecast (2019 to 2035)
5. Global Viral Vector Manufacturing Market by Workflow
5.1 Overview
5.2 Attractiveness Analysis by Workflow
5.3 Upstream Manufacturing : Trends and Forecast (2019 to 2035)
5.4 Downstream Manufacturing : Trends and Forecast (2019 to 2035)
6. Global Viral Vector Manufacturing Market by Application
6.1 Overview
6.2 Attractiveness Analysis by Application
6.3 Cell & Gene Therapy : Trends and Forecast (2019 to 2035)
6.4 Vaccinology : Trends and Forecast (2019 to 2035)
6.5 Research & Other Applications : Trends and Forecast (2019 to 2035)
7. Global Viral Vector Manufacturing Market by End Use
7.1 Overview
7.2 Attractiveness Analysis by End Use
7.3 Pharmaceutical & Biopharmaceutical : Trends and Forecast (2019 to 2035)
7.4 Research Institutes : Trends and Forecast (2019 to 2035)
7.5 Others : Trends and Forecast (2019 to 2035)
8. Regional Analysis
8.1 Overview
8.2 Global Viral Vector Manufacturing Market by Region
9. North American Viral Vector Manufacturing Market
9.1 Overview
9.2 North American Viral Vector Manufacturing Market by Type
9.3 North American Viral Vector Manufacturing Market by Application
9.4 The United States Viral Vector Manufacturing Market
9.5 Canadian Viral Vector Manufacturing Market
9.6 Mexican Viral Vector Manufacturing Market
10. European Viral Vector Manufacturing Market
10.1 Overview
10.2 European Viral Vector Manufacturing Market by Type
10.3 European Viral Vector Manufacturing Market by Application
10.4 German Viral Vector Manufacturing Market
10.5 French Viral Vector Manufacturing Market
10.6 Italian Viral Vector Manufacturing Market
10.7 Spanish Viral Vector Manufacturing Market
10.8 The United Kingdom Viral Vector Manufacturing Market
11. APAC Viral Vector Manufacturing Market
11.1 Overview
11.2 APAC Viral Vector Manufacturing Market by Type
11.3 APAC Viral Vector Manufacturing Market by Application
11.4 Chinese Viral Vector Manufacturing Market
11.5 Indian Viral Vector Manufacturing Market
11.6 Japanese Viral Vector Manufacturing Market
11.7 South Korean Viral Vector Manufacturing Market
11.8 Indonesian Viral Vector Manufacturing Market
12. RoW Viral Vector Manufacturing Market
12.1 Overview
12.2 RoW Viral Vector Manufacturing Market by Type
12.3 RoW Viral Vector Manufacturing Market by Application
12.4 Middle Eastern Viral Vector Manufacturing Market
12.5 South American Viral Vector Manufacturing Market
12.6 African Viral Vector Manufacturing Market
13. Competitor Analysis
13.1 Product Portfolio Analysis
13.2 Operational Integration
13.3 Porter’s Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
13.4 Market Share Analysis
14. Opportunities & Strategic Analysis
14.1 Value Chain Analysis
14.2 Growth Opportunity Analysis
14.2.1 Growth Opportunity by Type
14.2.2 Growth Opportunity by Workflow
14.2.3 Growth Opportunity by Application
14.2.4 Growth Opportunity by End Use
14.2.5 Growth Opportunity by Region
14.3 Emerging Trends in the Global Viral Vector Manufacturing Market
14.4 Strategic Analysis
14.4.1 New Product Development
14.4.2 Certification and Licensing
14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures
15. Company Profiles of the Leading Players Across the Value Chain
15.1 Competitive Analysis Overview
15.2 Merck
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
15.3 Lonza
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
15.4 Fujifilm Diosynth Biotechnologies
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
15.5 Thermo Fisher Scientific
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
15.6 Cobra Biologics
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
15.7 Catalent
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
15.8 Wuxi Biologics
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
15.9 Takara Bio
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
15.10 Waisman Biomanufacturing
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
15.11 Genezen Laboratories
  • Company Overview
  • Viral Vector Manufacturing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
16. Appendix
16.1 List of Figures
16.2 List of Tables
16.3 Research Methodology
16.4 Disclaimer
16.5 Copyright
16.6 Abbreviations and Technical Units
16.7 About Us
16.8 Contact Us
List of Figures
Chapter 1
Figure 1.1: Trends and Forecast for the Global Viral Vector Manufacturing Market
Chapter 2
Figure 2.1: Usage of Viral Vector Manufacturing Market
Figure 2.2: Classification of the Global Viral Vector Manufacturing Market
Figure 2.3: Supply Chain of the Global Viral Vector Manufacturing Market
Chapter 3
Figure 3.1: Trends of the Global GDP Growth Rate
Figure 3.2: Trends of the Global Population Growth Rate
Figure 3.3: Trends of the Global Inflation Rate
Figure 3.4: Trends of the Global Unemployment Rate
Figure 3.5: Trends of the Regional GDP Growth Rate
Figure 3.6: Trends of the Regional Population Growth Rate
Figure 3.7: Trends of the Regional Inflation Rate
Figure 3.8: Trends of the Regional Unemployment Rate
Figure 3.9: Trends of Regional Per Capita Income
Figure 3.10: Forecast for the Global GDP Growth Rate
Figure 3.11: Forecast for the Global Population Growth Rate
Figure 3.12: Forecast for the Global Inflation Rate
Figure 3.13: Forecast for the Global Unemployment Rate
Figure 3.14: Forecast for the Regional GDP Growth Rate
Figure 3.15: Forecast for the Regional Population Growth Rate
Figure 3.16: Forecast for the Regional Inflation Rate
Figure 3.17: Forecast for the Regional Unemployment Rate
Figure 3.18: Forecast for Regional Per Capita Income
Figure 3.19: Driver and Challenges of the Viral Vector Manufacturing Market
Chapter 4
Figure 4.1: Global Viral Vector Manufacturing Market by Type in 2019, 2026, and 2035
Figure 4.2: Trends of the Global Viral Vector Manufacturing Market ($M) by Type
Figure 4.3: Forecast for the Global Viral Vector Manufacturing Market ($M) by Type
Figure 4.4: Trends and Forecast for Adenovirus in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 4.5: Trends and Forecast for Retrovirus in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 4.6: Trends and Forecast for Adeno-Associated Virus in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 4.7: Trends and Forecast for Lentivirus in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 4.8: Trends and Forecast for Plasmid DNA in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 4.9: Trends and Forecast for Others in the Global Viral Vector Manufacturing Market (2019-2035)
Chapter 5
Figure 5.1: Global Viral Vector Manufacturing Market by Workflow in 2019, 2026, and 2035
Figure 5.2: Trends of the Global Viral Vector Manufacturing Market ($M) by Workflow
Figure 5.3: Forecast for the Global Viral Vector Manufacturing Market ($M) by Workflow
Figure 5.4: Trends and Forecast for Upstream Manufacturing in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 5.5: Trends and Forecast for Downstream Manufacturing in the Global Viral Vector Manufacturing Market (2019-2035)
Chapter 6
Figure 6.1: Global Viral Vector Manufacturing Market by Application in 2019, 2026, and 2035
Figure 6.2: Trends of the Global Viral Vector Manufacturing Market ($M) by Application
Figure 6.3: Forecast for the Global Viral Vector Manufacturing Market ($M) by Application
Figure 6.4: Trends and Forecast for Cell & Gene Therapy in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 6.5: Trends and Forecast for Vaccinology in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 6.6: Trends and Forecast for Research & Other Applications in the Global Viral Vector Manufacturing Market (2019-2035)
Chapter 7
Figure 7.1: Global Viral Vector Manufacturing Market by End Use in 2019, 2026, and 2035
Figure 7.2: Trends of the Global Viral Vector Manufacturing Market ($M) by End Use
Figure 7.3: Forecast for the Global Viral Vector Manufacturing Market ($M) by End Use
Figure 7.4: Trends and Forecast for Pharmaceutical & Biopharmaceutical in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 7.5: Trends and Forecast for Research Institutes in the Global Viral Vector Manufacturing Market (2019-2035)
Figure 7.6: Trends and Forecast for Others in the Global Viral Vector Manufacturing Market (2019-2035)
Chapter 8
Figure 8.1: Trends of the Global Viral Vector Manufacturing Market ($M) by Region (2019-2026)
Figure 8.2: Forecast for the Global Viral Vector Manufacturing Market ($M) by Region (2027-2035)
Chapter 9
Figure 9.1: Trends and Forecast for the North American Viral Vector Manufacturing Market (2019-2035)
Figure 9.2: North American Viral Vector Manufacturing Market by Type in 2019, 2026, and 2035
Figure 9.3: Trends of the North American Viral Vector Manufacturing Market ($M) by Type (2019-2026)
Figure 9.4: Forecast for the North American Viral Vector Manufacturing Market ($M) by Type (2027-2035)
Figure 9.5: North American Viral Vector Manufacturing Market by Workflow in 2019, 2026, and 2035
Figure 9.6: Trends of the North American Viral Vector Manufacturing Market ($M) by Workflow (2019-2026)
Figure 9.7: Forecast for the North American Viral Vector Manufacturing Market ($M) by Workflow (2027-2035)
Figure 9.8: Trends and Forecast for the United States Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 9.9: Trends and Forecast for the Mexican Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 9.10: Trends and Forecast for the Canadian Viral Vector Manufacturing Market ($M) (2019-2035)
Chapter 10
Figure 10.1: Trends and Forecast for the European Viral Vector Manufacturing Market (2019-2035)
Figure 10.2: European Viral Vector Manufacturing Market by Type in 2019, 2026, and 2035
Figure 10.3: Trends of the European Viral Vector Manufacturing Market ($M) by Type (2019-2026)
Figure 10.4: Forecast for the European Viral Vector Manufacturing Market ($M) by Type (2027-2035)
Figure 10.5: European Viral Vector Manufacturing Market by Workflow in 2019, 2026, and 2035
Figure 10.6: Trends of the European Viral Vector Manufacturing Market ($M) by Workflow (2019-2026)
Figure 10.7: Forecast for the European Viral Vector Manufacturing Market ($M) by Workflow (2027-2035)
Figure 10.8: Trends and Forecast for the German Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 10.9: Trends and Forecast for the French Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 10.10: Trends and Forecast for the Spanish Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 10.11: Trends and Forecast for the Italian Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 10.12: Trends and Forecast for the United Kingdom Viral Vector Manufacturing Market ($M) (2019-2035)
Chapter 11
Figure 11.1: Trends and Forecast for the APAC Viral Vector Manufacturing Market (2019-2035)
Figure 11.2: APAC Viral Vector Manufacturing Market by Type in 2019, 2026, and 2035
Figure 11.3: Trends of the APAC Viral Vector Manufacturing Market ($M) by Type (2019-2026)
Figure 11.4: Forecast for the APAC Viral Vector Manufacturing Market ($M) by Type (2027-2035)
Figure 11.5: APAC Viral Vector Manufacturing Market by Workflow in 2019, 2026, and 2035
Figure 11.6: Trends of the APAC Viral Vector Manufacturing Market ($M) by Workflow (2019-2026)
Figure 11.7: Forecast for the APAC Viral Vector Manufacturing Market ($M) by Workflow (2027-2035)
Figure 11.8: Trends and Forecast for the Japanese Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 11.9: Trends and Forecast for the Indian Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 11.10: Trends and Forecast for the Chinese Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 11.11: Trends and Forecast for the South Korean Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 11.12: Trends and Forecast for the Indonesian Viral Vector Manufacturing Market ($M) (2019-2035)
Chapter 12
Figure 12.1: Trends and Forecast for the RoW Viral Vector Manufacturing Market (2019-2035)
Figure 12.2: RoW Viral Vector Manufacturing Market by Type in 2019, 2026, and 2035
Figure 12.3: Trends of the RoW Viral Vector Manufacturing Market ($M) by Type (2019-2026)
Figure 12.4: Forecast for the RoW Viral Vector Manufacturing Market ($M) by Type (2027-2035)
Figure 12.5: RoW Viral Vector Manufacturing Market by Workflow in 2019, 2026, and 2035
Figure 12.6: Trends of the RoW Viral Vector Manufacturing Market ($M) by Workflow (2019-2026)
Figure 12.7: Forecast for the RoW Viral Vector Manufacturing Market ($M) by Workflow (2027-2035)
Figure 12.8: Trends and Forecast for the Middle Eastern Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 12.9: Trends and Forecast for the South American Viral Vector Manufacturing Market ($M) (2019-2035)
Figure 12.10: Trends and Forecast for the African Viral Vector Manufacturing Market ($M) (2019-2035)
Chapter 13
Figure 13.1: Porter’s Five Forces Analysis of the Global Viral Vector Manufacturing Market
Figure 13.2: Market Share (%) of Top Players in the Global Viral Vector Manufacturing Market (2025)
Chapter 14
Figure 14.1: Growth Opportunities for the Global Viral Vector Manufacturing Market by Type
Figure 14.2: Growth Opportunities for the Global Viral Vector Manufacturing Market by Workflow
Figure 14.3: Growth Opportunities for the Global Viral Vector Manufacturing Market by Application
Figure 14.4: Growth Opportunities for the Global Viral Vector Manufacturing Market by End Use
Figure 14.5: Growth Opportunities for the Global Viral Vector Manufacturing Market by Region
Figure 14.6: Emerging Trends in the Global Viral Vector Manufacturing Market
List of Tables
Chapter 1
Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Viral Vector Manufacturing Market by Type, Workflow, Application, and End Use
Table 1.2: Attractiveness Analysis for the Viral Vector Manufacturing Market by Region
Table 1.3: Global Viral Vector Manufacturing Market Parameters and Attributes
Chapter 3
Table 3.1: Trends of the Global Viral Vector Manufacturing Market (2019-2026)
Table 3.2: Forecast for the Global Viral Vector Manufacturing Market (2027-2035)
Chapter 4
Table 4.1: Attractiveness Analysis for the Global Viral Vector Manufacturing Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Viral Vector Manufacturing Market (2019-2026)
Table 4.3: Market Size and CAGR of Various Type in the Global Viral Vector Manufacturing Market (2027-2035)
Table 4.4: Trends of Adenovirus in the Global Viral Vector Manufacturing Market (2019-2026)
Table 4.5: Forecast for Adenovirus in the Global Viral Vector Manufacturing Market (2027-2035)
Table 4.6: Trends of Retrovirus in the Global Viral Vector Manufacturing Market (2019-2026)
Table 4.7: Forecast for Retrovirus in the Global Viral Vector Manufacturing Market (2027-2035)
Table 4.8: Trends of Adeno-Associated Virus in the Global Viral Vector Manufacturing Market (2019-2026)
Table 4.9: Forecast for Adeno-Associated Virus in the Global Viral Vector Manufacturing Market (2027-2035)
Table 4.10: Trends of Lentivirus in the Global Viral Vector Manufacturing Market (2019-2026)
Table 4.11: Forecast for Lentivirus in the Global Viral Vector Manufacturing Market (2027-2035)
Table 4.12: Trends of Plasmid DNA in the Global Viral Vector Manufacturing Market (2019-2026)
Table 4.13: Forecast for Plasmid DNA in the Global Viral Vector Manufacturing Market (2027-2035)
Table 4.14: Trends of Others in the Global Viral Vector Manufacturing Market (2019-2026)
Table 4.15: Forecast for Others in the Global Viral Vector Manufacturing Market (2027-2035)
Chapter 5
Table 5.1: Attractiveness Analysis for the Global Viral Vector Manufacturing Market by Workflow
Table 5.2: Market Size and CAGR of Various Workflow in the Global Viral Vector Manufacturing Market (2019-2026)
Table 5.3: Market Size and CAGR of Various Workflow in the Global Viral Vector Manufacturing Market (2027-2035)
Table 5.4: Trends of Upstream Manufacturing in the Global Viral Vector Manufacturing Market (2019-2026)
Table 5.5: Forecast for Upstream Manufacturing in the Global Viral Vector Manufacturing Market (2027-2035)
Table 5.6: Trends of Downstream Manufacturing in the Global Viral Vector Manufacturing Market (2019-2026)
Table 5.7: Forecast for Downstream Manufacturing in the Global Viral Vector Manufacturing Market (2027-2035)
Chapter 6
Table 6.1: Attractiveness Analysis for the Global Viral Vector Manufacturing Market by Application
Table 6.2: Market Size and CAGR of Various Application in the Global Viral Vector Manufacturing Market (2019-2026)
Table 6.3: Market Size and CAGR of Various Application in the Global Viral Vector Manufacturing Market (2027-2035)
Table 6.4: Trends of Cell & Gene Therapy in the Global Viral Vector Manufacturing Market (2019-2026)
Table 6.5: Forecast for Cell & Gene Therapy in the Global Viral Vector Manufacturing Market (2027-2035)
Table 6.6: Trends of Vaccinology in the Global Viral Vector Manufacturing Market (2019-2026)
Table 6.7: Forecast for Vaccinology in the Global Viral Vector Manufacturing Market (2027-2035)
Table 6.8: Trends of Research & Other Applications in the Global Viral Vector Manufacturing Market (2019-2026)
Table 6.9: Forecast for Research & Other Applications in the Global Viral Vector Manufacturing Market (2027-2035)
Chapter 7
Table 7.1: Attractiveness Analysis for the Global Viral Vector Manufacturing Market by End Use
Table 7.2: Market Size and CAGR of Various End Use in the Global Viral Vector Manufacturing Market (2019-2026)
Table 7.3: Market Size and CAGR of Various End Use in the Global Viral Vector Manufacturing Market (2027-2035)
Table 7.4: Trends of Pharmaceutical & Biopharmaceutical in the Global Viral Vector Manufacturing Market (2019-2026)
Table 7.5: Forecast for Pharmaceutical & Biopharmaceutical in the Global Viral Vector Manufacturing Market (2027-2035)
Table 7.6: Trends of Research Institutes in the Global Viral Vector Manufacturing Market (2019-2026)
Table 7.7: Forecast for Research Institutes in the Global Viral Vector Manufacturing Market (2027-2035)
Table 7.8: Trends of Others in the Global Viral Vector Manufacturing Market (2019-2026)
Table 7.9: Forecast for Others in the Global Viral Vector Manufacturing Market (2027-2035)
Chapter 8
Table 8.1: Market Size and CAGR of Various Regions in the Global Viral Vector Manufacturing Market (2019-2026)
Table 8.2: Market Size and CAGR of Various Regions in the Global Viral Vector Manufacturing Market (2027-2035)
Chapter 9
Table 9.1: Trends of the North American Viral Vector Manufacturing Market (2019-2026)
Table 9.2: Forecast for the North American Viral Vector Manufacturing Market (2027-2035)
Table 9.3: Market Size and CAGR of Various Type in the North American Viral Vector Manufacturing Market (2019-2026)
Table 9.4: Market Size and CAGR of Various Type in the North American Viral Vector Manufacturing Market (2027-2035)
Table 9.5: Market Size and CAGR of Various Workflow in the North American Viral Vector Manufacturing Market (2019-2026)
Table 9.6: Market Size and CAGR of Various Workflow in the North American Viral Vector Manufacturing Market (2027-2035)
Table 9.7: Trends and Forecast for the United States Viral Vector Manufacturing Market (2019-2035)
Table 9.8: Trends and Forecast for the Mexican Viral Vector Manufacturing Market (2019-2035)
Table 9.9: Trends and Forecast for the Canadian Viral Vector Manufacturing Market (2019-2035)
Chapter 10
Table 10.1: Trends of the European Viral Vector Manufacturing Market (2019-2026)
Table 10.2: Forecast for the European Viral Vector Manufacturing Market (2027-2035)
Table 10.3: Market Size and CAGR of Various Type in the European Viral Vector Manufacturing Market (2019-2026)
Table 10.4: Market Size and CAGR of Various Type in the European Viral Vector Manufacturing Market (2027-2035)
Table 10.5: Market Size and CAGR of Various Workflow in the European Viral Vector Manufacturing Market (2019-2026)
Table 10.6: Market Size and CAGR of Various Workflow in the European Viral Vector Manufacturing Market (2027-2035)
Table 10.7: Trends and Forecast for the German Viral Vector Manufacturing Market (2019-2035)
Table 10.8: Trends and Forecast for the French Viral Vector Manufacturing Market (2019-2035)
Table 10.9: Trends and Forecast for the Spanish Viral Vector Manufacturing Market (2019-2035)
Table 10.10: Trends and Forecast for the Italian Viral Vector Manufacturing Market (2019-2035)
Table 10.11: Trends and Forecast for the United Kingdom Viral Vector Manufacturing Market (2019-2035)
Chapter 11
Table 11.1: Trends of the APAC Viral Vector Manufacturing Market (2019-2026)
Table 11.2: Forecast for the APAC Viral Vector Manufacturing Market (2027-2035)
Table 11.3: Market Size and CAGR of Various Type in the APAC Viral Vector Manufacturing Market (2019-2026)
Table 11.4: Market Size and CAGR of Various Type in the APAC Viral Vector Manufacturing Market (2027-2035)
Table 11.5: Market Size and CAGR of Various Workflow in the APAC Viral Vector Manufacturing Market (2019-2026)
Table 11.6: Market Size and CAGR of Various Workflow in the APAC Viral Vector Manufacturing Market (2027-2035)
Table 11.7: Trends and Forecast for the Japanese Viral Vector Manufacturing Market (2019-2035)
Table 11.8: Trends and Forecast for the Indian Viral Vector Manufacturing Market (2019-2035)
Table 11.9: Trends and Forecast for the Chinese Viral Vector Manufacturing Market (2019-2035)
Table 11.10: Trends and Forecast for the South Korean Viral Vector Manufacturing Market (2019-2035)
Table 11.11: Trends and Forecast for the Indonesian Viral Vector Manufacturing Market (2019-2035)
Chapter 12
Table 12.1: Trends of the RoW Viral Vector Manufacturing Market (2019-2026)
Table 12.2: Forecast for the RoW Viral Vector Manufacturing Market (2027-2035)
Table 12.3: Market Size and CAGR of Various Type in the RoW Viral Vector Manufacturing Market (2019-2026)
Table 12.4: Market Size and CAGR of Various Type in the RoW Viral Vector Manufacturing Market (2027-2035)
Table 12.5: Market Size and CAGR of Various Workflow in the RoW Viral Vector Manufacturing Market (2019-2026)
Table 12.6: Market Size and CAGR of Various Workflow in the RoW Viral Vector Manufacturing Market (2027-2035)
Table 12.7: Trends and Forecast for the Middle Eastern Viral Vector Manufacturing Market (2019-2035)
Table 12.8: Trends and Forecast for the South American Viral Vector Manufacturing Market (2019-2035)
Table 12.9: Trends and Forecast for the African Viral Vector Manufacturing Market (2019-2035)
Chapter 13
Table 13.1: Product Mapping of Viral Vector Manufacturing Suppliers Based on Segments
Table 13.2: Operational Integration of Viral Vector Manufacturing Manufacturers
Table 13.3: Rankings of Suppliers Based on Viral Vector Manufacturing Revenue
Chapter 14
Table 14.1: New Product Launches by Major Viral Vector Manufacturing Producers (2019-2026)
Table 14.2: Certification Acquired by Major Competitor in the Global Viral Vector Manufacturing Market

Companies Mentioned

  • Merck
  • Lonza
  • FUJIFILM Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent
  • Wuxi Biologics
  • Takara Bio
  • Waisman Biomanufacturing
  • Genezen laboratories

Methodology

The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:

  • In-depth interviews of the major players in the market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.

Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.

Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

 

Loading
LOADING...